Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)
Cooper, H.L., Healy, E., Theaker, J.M. and Friedmann, P.S. (2003) Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clinical and Experimental Dermatology, 28, (4), 366-368. (doi:10.1046/j.1365-2230.2003.01283.x).
Full text not available from this repository.
We describe a 54-year-old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and have been associated with considerable side-effects. The anti-CD20 monoclonal antibody, Rituximab (MabThera, Roche), was trialled with significant benefit. We discuss its potential mechanism of action.
|Subjects:||R Medicine > RL Dermatology|
|Divisions:||University Structure - Pre August 2011 > School of Medicine > Infection, Inflammation and Repair
|Date Deposited:||26 Apr 2006|
|Last Modified:||01 Dec 2011 04:39|
|Contributors:||Cooper, H.L. (Author)
Healy, E. (Author)
Theaker, J.M. (Author)
Friedmann, P.S. (Author)
|Contact Email Address:||P.S.Friedmann@soton.ac.uk|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)